Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women

Psychiatry Research

Volumn 187, Issue 1-2, 2011, Pages 74-79

  Houston, John ^a   Dharia, Sweta ^b   Bishop, Jeffrey R ^c   Ellingrod, Vicki L ^d   Fijal, Bonnie ^a   Jacobson, Jennie G ^a   Hoffmann, Vicki P ^a  

^a Lilly USA   (United States)

^b UnitedHealth Group Alliances   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

ANKK1; Antipsychotic agents; Dopamine receptors; DRD2; Olanzapine; Prolactin

Indexed keywords

ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1 PROTEIN; DOPAMINE 2 RECEPTOR; FLUOXETINE; LAMOTRIGINE; MEMBRANE PROTEIN; OLANZAPINE; PLACEBO; PROLACTIN; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM;

5' UNTRANSLATED REGION; ADULT; AMENORRHEA; ANORGASMIA; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BORDERLINE STATE; BREAST HYPERTROPHY; BREAST TENDERNESS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EJACULATION DISORDER; EXON; FEMALE; GENETIC ASSOCIATION; HUMAN; INTRON; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MANIA; META ANALYSIS; MUTATIONAL ANALYSIS; OPEN STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG COMBINATIONS; FEMALE; FLUOXETINE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; META-ANALYSIS AS TOPIC; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLACTIN; PROTEIN-SERINE-THREONINE KINASES; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; SEX CHARACTERISTICS;

EID: 79953087810     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.10.020     Document Type: Article

References (29)

1. Aklillu E., Kalow W., Endrenyi L., Harper P., Miura J., Ozdemir V. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenetics and Genomics 2007, 17:989-993.
2. Alfaro C.L., Wudarsky M., Nicolson R., Gochman P., Sporn A., Lenane M., Rapoport J.L. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Journal of Child and Adolescent Psychopharmacology 2002, 12:83-91.
3. Arinami T., Gao M., Hamaguchi H., Toru M.A. Functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics 1997, 6:577-582.
4. Barret J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
5. Biller B.M., Coughlin J.F., Saxe V., Schoenfeld D., Spratt D.I., Klibanski A. Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstetrics and Gynecology 1991, 78:996-1001.
6. Brown E.B., McElroy S.L., Keck P.E., Deldar A., Adams D.H., Tohen M., Williamson D.J. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I disorder. The Journal of Clinical Psychiatry 2006, 67:1025-1033.
7. Calarge C.A., Ellingrod V.L., Acion L., Miller D.D., Moline J., Tansey M.J., Schlechte J.A. Variants of the dopamine D2 receptor gene and risperidone-induced hyperlactinemia in children and adolescents. Pharmacogenetics and Genomics 2009, 19:373-382.
8. Duan J., Wainwright M.S., Comeron J.M., Saitou N., Sanders A.R., Gelernter J., Gejman P.V. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human Molecular Genetics 2003, 12:205-216.
9. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Lochner A., Faggart M., Liu-Cordero S.N., Rotimi C., Adeyemo A., Cooper R., Ward R., Lander E.S., Daly M.J., Altshuler D. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
10. Halbreich U., Rojansky N., Palter S., Hreshchyshyn M., Kreeger J., Bakhai Y., Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosomatic Medicine 1995, 57:485-491.
11. Hedges L.V., Olkin I. Statistical Methods for Meta-Analysis 1985, Academic Press, Inc., San Diego.
12. Houston J.P., Fijal B., Heinloth A.N., Adams D.H. Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Psychiatry Research 2010, 175:171-172.
13. Jurinke C., van den Boom D., Cantor C.R., Koster H. Automated genotyping using the DNA MassArray technology. Methods in Molecular Biology 2002, 187:179-192.
14. Kwon J.S., Kim E., Kang D.-H., Choi J.S., Yu K.-S., Jang I.-J., Shin S.-G. TaqA polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. European Neuropsychopharmacology 2008, 18:897-907.
15. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. The British Journal of Psychiatry 2004, 184:503-508.
16. Mihara K., Kondo T., Suzuki A., Yasui N., Nagashima U., Ono S., Otani K., Kaneko S. Prolactin response to nemonapride, a selective antagonist of D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology (Berlin) 2000, 149:246-250.
17. Noble E.P., Zhang X., Ritchie T.L., Sparkes R.S. Haplotypes at the DRD2 locus and severe alcoholism. American Journal of Medical Genetics 2000, 96:622-631.
18. Petty R.G. Prolactin and antipsychotic medications: mechanism of action. Schizophrenia Research 1999, 35(Suppl):S67-S73.
19. Sawamura K., Suzuki Y., Fukui N., Sugai T., Someya T. Gender differences in prolactin elevation induced by olanzapine in Japanese drug-naïve schizophrenic patients. Progress in Neuropsychopharmacology & Biological Psychiatry 2006, 30:1511-1514.
20. Schulz S.C., Zanarini M.C., Bateman A., Bohus M., Detke H.C., Trzaskoma Q., Tanaka Y., Lin D., Deberdt W., Corya S. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomized double-blind placebo controlled study. The British Journal of Psychiatry 2008, 193:485-492.
21. Thase M.E., Corya S.A., Osuntokun O., Case M., Henley D.B., Sanger T.M., Watson S.B., Dubé S. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. The Journal of Clinical Psychiatry 2007, 68:224-236.
22. Thompson J., Thomas N., Singleton A., Piggott M., Lloyd S., Perry E.K., Morris C.M., Perry R.H., Ferrier I.N., Court J.A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997, 7:479-484.
23. Tohen M., Vieta E., Goodwin G.M., Sun B., Amsterdam J.D., Banov M., Shekhar A., Aaronson S.T., Bardenstein L., Grecu-Gabos I., Tochilov V., Prelipceanu D., Oliff H.S., Kryzhanovskaya L., Bowden C. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. The Journal of Clinical Psychiatry 2008, 69:1776-1779.
24. Wieck A., Haddad P.M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. The British Journal of Psychiatry 2003, 182:199-204.
25. Yasui-Furukori N., Saito M., Tsuchimine S., Nakagami T., Sato Y., Sugawara N., Kaneko S. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Progress in Neuropsychopharmacololgy and Biological Psychatry 2008, 32:1491-1495.
26. Young R.M., Lawford B.R., Barnes M., Burton S.C., Ritchie T., Ward W.K., Noble E.P. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2 A1 allele. The British Journal of Psychiatry 2004, 185:147-151.
27. Zai C.C., Romano-Silva M.A., Hwang R., Zai G.C., DeLuca B., Muller D.J. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophrenia Research 2004, 2004:248-252.
28. Zanarini M.C., Schulz S.C., Detke H.C., Tanaka Y., Zhao F., Lin D., Deberdt W., Corya S. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. European Psychiatry 2007, 22(Suppl 1):172-173. (abstract P249).
29. Zhang Y., Bertolino A., Fazio L., Blasi G., Rampino A., Romano R., Lee M.L., Xiao T., Papp A., Wang D., Sadée W. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20552-20557.